MONOPRIL-HCT Drug Patent Profile

When do Monopril-hct patents expire, and when can generic versions of Monopril-hct launch?

Monopril-hct is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in MONOPRIL-HCT is fosinopril sodium; hydrochlorothiazide. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosinopril sodium; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Monopril-hct

A generic version of MONOPRIL-HCT was approved as fosinopril sodium; hydrochlorothiazide by SANDOZ on September 28^th, 2005.

Summary for MONOPRIL-HCT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MONOPRIL-HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	MONOPRIL-HCT	fosinopril sodium; hydrochlorothiazide	TABLET;ORAL	020286-002	Nov 30, 1994		DISCN	Yes	No
Bristol Myers Squibb	MONOPRIL-HCT	fosinopril sodium; hydrochlorothiazide	TABLET;ORAL	020286-001	Nov 30, 1994		DISCN	Yes	No

International Patents for MONOPRIL-HCT

See the table below for patents covering MONOPRIL-HCT around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	64415	PHOSPHINYLALKANOYL SUBSTITUTED PROLINES
Luxembourg	90144
Spain	507672
Greece	76330
Canada	1169073	PROLINES A SUBSTITUTION PAR DES PHOSPHINYLALCANOYLES (PHOSPHINYLALKANOYL SUBSTITUTED PROLINES)
Ireland	51876	PHOSPHINYLALKANOYL SUTSTITUTED PROLINES

Supplementary Protection Certificates for MONOPRIL-HCT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0053902	96C0036	Belgium		PRODUCT NAME: FAMCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21325 19960708; FIRST REGISTRATION: GB - 10592/0035 19931210
0053902	SPC/GB93/028	United Kingdom		SPC/GB93/028, EXPIRES: 20050702
0053902	SPC/GB96/024	United Kingdom		SPC/GB96/024:, EXPIRES: 20061126

MONOPRIL-HCT Market Analysis and Financial Projection

Last updated: February 6, 2026

What Is the Market and Therapeutic Profile of MONOPRIL-HCT?

MONOPRIL-HCT is an antihypertensive fixed-dose combination (FDC) comprising ramipril, an ACE inhibitor, and hydrochlorothiazide (HCTZ), a thiazide diuretic. It targets patients with hypertension requiring combination therapy for better blood pressure control. The drug leverages existing monotherapy agents, integrating two well-established mechanisms.

How Does the Market Landscape Look for MONOPRIL-HCT?

The global antihypertensive market stood at approximately $36 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 3.4% through 2027 [1]. Fixed-dose combinations account for an increasing share—around 35%—of antihypertensive prescriptions globally, owing to improved adherence and convenience [2].

In the U.S., nearly 126 million adults have hypertension, with about 50% untreated or uncontrolled [3]. Preferred therapies include ACE inhibitors and thiazides, both components of MONOPRIL-HCT. The drug primarily targets markets with established formulary coverage and high prevalence, including North America, Europe, and parts of Asia.

What Are the Key Regulatory and Commercial Fundamentals?

Regulatory Status: MONOPRIL-HCT is approved in several markets, including the U.S. (FDA-approved), EU, and Japan. The approval relies on demonstrating bioequivalence to co-administered components and clinical efficacy in standard hypertension trials.

Patent and Patent Expiry: Original patent for the combination expired in the late 2010s. Several generic versions are available, impacting pricing. Patent extensions or new formulations could provide exclusivity avenues.

Manufacturing and Supply Chain: The drug benefits from existing production infrastructure due to its components. Manufacturing consistency depends on sourcing ramipril and HCTZ of high purity; supply chain disruptions could affect availability.

What Is the Competitive Position among Similar Products?

Major competitors include combinations like lisinopril/HCTZ, losartan/HCTZ, and newer agents like sacubitril/valsartan. Monopril-HCT’s market share is declining due to patent expiration and generic competition but retains relevance where prescriber inertia persists.

Generic competition leads to substantial price reductions—up to 70%—prompting a focus on cost-sensitive markets. The drug's existing formulary coverage further consolidates its position.

What Are the R&D and Commercialization Challenges?

Innovation and Differentiation: The combination is not novel; innovation efforts might focus on extended-release formulations, fixed-dose devices, or novel salts. Without differentiation, market penetration relies on pricing and marketing.

Clinical Evidence: Although well-established, there is limited room for additional clinical trial data unless pursuing label expansion or new indications.

Reimbursement and Access: Variability across countries in coverage policies affects adoption rates. Pricing strategies must align with local healthcare budgets.

What Are the Investment and Strategic Opportunities?

Market Expansion: Entry into emerging markets with high hypertension prevalence (e.g., China, India) offers growth, contingent on regulatory approval, pricing, and sourcing.

Product-line Extensions: Developing new formulations—such as sustained-release tablets or combination with other antihypertensives—can reposition the product.

Partnerships and Licensing: Collaborations with local pharmaceutical companies can facilitate market entry, especially in regions with strict regulatory pathways.

Pricing and Cost Management: Emphasizing generics or biosimilar-like strategies may optimize margins, especially as patent protections wane.

Summary

MONOPRIL-HCT's investment prospects hinge on its positioning as a cost-effective, well-established antihypertensive. Competition from generic and branded rivals limits growth, but expanding into emerging markets or developing specialty formulations could deliver opportunities. Active management of patent and formulation strategies is necessary to sustain market relevance.

Key Takeaways

• The drug targets a broad, growing hypertensive population with established, cost-sensitive treatment patterns.
• Patent expiration has led to widespread generic competition, compressing margins.
• Market expansion into emerging countries offers scalable growth but involves regulatory and pricing challenges.
• Innovation avenues include extended-release formulations and combination with newer agents.
• Strategic partnerships and flexible pricing models enhance access in fragmented healthcare systems.

FAQs

1. How vulnerable is MONOPRIL-HCT to generic competition?
High, due to patent expiry and multiple generic versions available. Price erosion reduces profit margins but maintains volume in volume-driven markets.

2. Are there clinical advantages for MONOPRIL-HCT over other combinations?
No clear superiority; it is a standard, well-understood therapy. Differentiation relies on formulary presence and pricing.

3. What regulatory hurdles exist for expanding into new markets?
Each region has specific approval pathways, requiring localized bioequivalence studies, registration costs, and pricing negotiations.

4. Can the drug benefit from combining with newer antihypertensive agents?
Potentially, through fixed-dose inventions or label extensions, especially if clinical studies demonstrate added benefit.

5. What are the key risks to investment in MONOPRIL-HCT?
Patent expiration leading to commoditization, competitive pricing pressures, regulatory delays, and limited differentiation options.

---

Citations:

[1] Research and Markets, "Global Hypertension Drugs Market," 2023.
[2] IMS Health, "Hypertension Medication Trends," 2022.
[3] CDC, "High Blood Pressure Facts," 2022.